-
Mashup Score: 0Blinatumomab Receives Full Approval for MRD-Positive B-Cell ALL - 10 month(s) ago
The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Glofitamab Gains Accelerated Approval for Relapsed/Refractory DLBCL - 10 month(s) ago
Glofitamab has received accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Glofitamab has received accelerated approval for the treatment of patients with R/R DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma. #oncology #FDA #approval #nursing #DLBCL #lymsm https://t.co/JXceivOXun
-
-
Mashup Score: 0Blinatumomab Receives Full Approval for MRD-Positive B-Cell ALL - 10 month(s) ago
The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breaking: Blinatumomab Receives Full Approval for MRD-Positive B-Cell ALL #oncology #nursing #oncologynursing #FDA #approval #BreakingNews #leusm #ALL https://t.co/GGYwYdXqui
-
-
Mashup Score: 0Glofitamab Gains Accelerated Approval for Relapsed/Refractory DLBCL - 10 month(s) ago
Glofitamab has received accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Glofitamab has received accelerated approval for the treatment of patients with R/R DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma. #oncology #FDA #approval #nursing #DLBCL #lymsm https://t.co/0xmLj51tPy
-
-
Mashup Score: 0Glofitamab Gains Accelerated Approval for Relapsed/Refractory DLBCL - 10 month(s) ago
Glofitamab has received accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breaking: Glofitamab Gains Accelerated Approval for Relapsed/Refractory DLBCL #oncology #FDA #approval #nursing #DLBCL #lymsm https://t.co/KPbtkgO9gm
-
-
Mashup Score: 0Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL - 11 month(s) ago
The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL #lymsm #oncology #nursing #DLBCL #FDA #approval https://t.co/BPMyjFWFjy
-
-
Mashup Score: 0Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL - 11 month(s) ago
The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breaking: Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL #lymsm #oncology #nursing #DLBCL #FDA #approval https://t.co/BPMyjFWFjy
-
-
Mashup Score: 0FDA approves fezolinetant for vasomotor symptoms - 12 month(s) ago
Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with menopause.
Source: Contemporary OB/GYNCategories: Latest Headlines, OBGYNTweet-
ICYMI: Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with #menopause. #FDA #Approval FDA Approval: https://t.co/2WWynvU99C
-
-
Mashup Score: 0Polatuzumab Vedotin Approved in Combination with R-CHP for Treatment-Naïve DLBCL, High-Grade B-Cell Lymphoma - 1 year(s) ago
Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma. #oncology #nursing #lymsm #FDA #approval https://t.co/7T7c0Ca56e
-
-
Mashup Score: 0Polatuzumab Vedotin Approved in Combination with R-CHP for Treatment-Naïve DLBCL, High-Grade B-Cell Lymphoma - 1 year(s) ago
Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: Polatuzumab Vedotin Approved in Combination with R-CHP for Treatment-Naïve DLBCL, High-Grade B-Cell Lymphoma #oncology #nursing #lymsm #FDA #approval https://t.co/gg42IH5dxU
-
The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia. #oncology #nursing #oncologynursing #FDA #approval #BreakingNews #leusm #ALL https://t.co/x69mBZCMmD